Kishida T, Chen F, Lerman M I, Zbar B
Laboratory of Immunobiology, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201, USA.
J Med Genet. 1995 Dec;32(12):938-41. doi: 10.1136/jmg.32.12.938.
Von Hippel-Lindau disease (VHL) is an inherited disorder characterised by a predisposition to develop tumours in the eyes, central nervous system, kidneys, and adrenal glands. Recently the VHL gene was cloned and shown to be mutated in 75% of US and Canadian VHL families. To develop simple, rapid methods for the detection of mutations found in large numbers of affected people, we designed based on the primer specified restriction site modification method. These tests have proved useful in identifying asymptomatic mutated VHL gene carriers who have the nt 505 T to C mutation or the nt 686 T to C mutation. Together with an MspI digestion test which can detect a mutation hot spot in codon 238, polymerase chain reaction/restriction endonuclease based tests can now detect VHL mutations in more than 50% of VHL type 2 families.
冯·希佩尔-林道病(VHL)是一种遗传性疾病,其特征是易在眼睛、中枢神经系统、肾脏和肾上腺发生肿瘤。最近,VHL基因被克隆出来,并且在美国和加拿大75%的VHL家族中发现该基因发生了突变。为了开发出简单、快速的方法来检测大量患者中发现的突变,我们基于引物特异性限制位点修饰方法进行了设计。这些检测方法已被证明可用于识别具有nt 505 T到C突变或nt 686 T到C突变的无症状VHL基因突变携带者。结合能够检测密码子238突变热点的MspI消化检测,基于聚合酶链反应/限制性内切酶的检测现在可以在超过50%的2型VHL家族中检测到VHL突变。